Cobiprostone is DOA for OM too. I've a posted about that in the past. The value here is wringing as much out of amitiza as possible then selling out. They can add more value to the company by shutting down non-amitiza R&D.
I've been buying every day. What's it to you? I see Jeremy Zhu at Wedbush took a swing. The oil assets are totally discounted to zero at this price. I think this is still a winner and you should hold on to your shares.